These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 10802128)
1. Efficacy of intravenous citalopram compared with oral citalopram for severe depression. Safety and efficacy data from a double-blind, double-dummy trial. Guelfi JD; Strub N; Loft H J Affect Disord; 2000 Jun; 58(3):201-9. PubMed ID: 10802128 [TBL] [Abstract][Full Text] [Related]
2. A double-blind double-dummy study of citalopram comparing infusion versus oral administration. Baumann P; Nil R; Bertschy G; Jecker A; Brändli H; Morand J; Kasas A; Vuagniaux O; Ramseier F J Affect Disord; 1998 Jun; 49(3):203-10. PubMed ID: 9629950 [TBL] [Abstract][Full Text] [Related]
3. A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia. Karlsson I; Godderis J; Augusto De Mendonça Lima C; Nygaard H; Simányi M; Taal M; Eglin M Int J Geriatr Psychiatry; 2000 Apr; 15(4):295-305. PubMed ID: 10767728 [TBL] [Abstract][Full Text] [Related]
4. Citalopram and viloxazine in the treatment of depression by means of slow drop infusion. A double-blind comparative trial. Bouchard JM; Strub N; Nil R J Affect Disord; 1997 Oct; 46(1):51-8. PubMed ID: 9387086 [TBL] [Abstract][Full Text] [Related]
7. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. Feighner JP; Overø K J Clin Psychiatry; 1999 Dec; 60(12):824-30. PubMed ID: 10665628 [TBL] [Abstract][Full Text] [Related]
8. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Lepola UM; Loft H; Reines EH Int Clin Psychopharmacol; 2003 Jul; 18(4):211-7. PubMed ID: 12817155 [TBL] [Abstract][Full Text] [Related]
9. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128 [TBL] [Abstract][Full Text] [Related]
10. [Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram, in patients with major depressive disorder--the navigade switch study]. Schmitt L; Arbus C; Tonnoir B Encephale; 2006; 32(2 Pt 1):270-7. PubMed ID: 16910629 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Llorca PM; Azorin JM; Despiegel N; Verpillat P Int J Clin Pract; 2005 Mar; 59(3):268-75. PubMed ID: 15857321 [TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram in patients with major depressive disorder. Schmitt L; Tonnoir B; Arbus C Neuropsychobiology; 2006; 54(4):201-7. PubMed ID: 17337913 [TBL] [Abstract][Full Text] [Related]
13. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Kraus MR; Schäfer A; Schöttker K; Keicher C; Weissbrich B; Hofbauer I; Scheurlen M Gut; 2008 Apr; 57(4):531-6. PubMed ID: 18079286 [TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Colonna L; Andersen HF; Reines EH Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder. Langworth S; Bodlund O; Agren H J Clin Psychopharmacol; 2006 Apr; 26(2):121-7. PubMed ID: 16633139 [TBL] [Abstract][Full Text] [Related]
16. Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice. Kyle CJ; Petersen HE; Overø KF Depress Anxiety; 1998; 8(4):147-53. PubMed ID: 9871816 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. Versiani M; Moreno R; Ramakers-van Moorsel CJ; Schutte AJ; CNS Drugs; 2005; 19(2):137-46. PubMed ID: 15697327 [TBL] [Abstract][Full Text] [Related]
18. Citalopram for Acute and Preventive Efficacy in Bipolar Depression (CAPE-BD): A Randomized, Double-Blind, Placebo-Controlled Trial. Ghaemi SN; Whitham EA; Vohringer PA; Barroilhet SA; Amerio A; Sverdlov O; Patkar AA J Clin Psychiatry; 2021 Jan; 82(1):. PubMed ID: 33434956 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study. Kim JS; Lee EJ; Chang DI; Park JH; Ahn SH; Cha JK; Heo JH; Sohn SI; Lee BC; Kim DE; Kim HY; Kim S; Kwon DY; Kim J; Seo WK; Lee J; Park SW; Koh SH; Kim JY; Choi-Kwon S; Lancet Psychiatry; 2017 Jan; 4(1):33-41. PubMed ID: 28012485 [TBL] [Abstract][Full Text] [Related]
20. Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy. Hochstrasser B; Isaksen PM; Koponen H; Lauritzen L; Mahnert FA; Rouillon F; Wade AG; Andersen M; Pedersen SF; Swart JC; Nil R Br J Psychiatry; 2001 Apr; 178():304-10. PubMed ID: 11282808 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]